CN108815187A - A kind of preparation and its application method comprising person joint's liquid excretion body - Google Patents
A kind of preparation and its application method comprising person joint's liquid excretion body Download PDFInfo
- Publication number
- CN108815187A CN108815187A CN201810803915.4A CN201810803915A CN108815187A CN 108815187 A CN108815187 A CN 108815187A CN 201810803915 A CN201810803915 A CN 201810803915A CN 108815187 A CN108815187 A CN 108815187A
- Authority
- CN
- China
- Prior art keywords
- preparation
- excretion body
- person joint
- liquid excretion
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 89
- 230000029142 excretion Effects 0.000 title claims abstract description 81
- 239000007788 liquid Substances 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 239000002904 solvent Substances 0.000 claims abstract description 25
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 23
- 229930182817 methionine Natural products 0.000 claims abstract description 23
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 22
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 22
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims abstract description 22
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 22
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 22
- 239000008367 deionised water Substances 0.000 claims abstract description 21
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 21
- 229920000151 polyglycol Polymers 0.000 claims abstract description 15
- 239000010695 polyglycol Substances 0.000 claims abstract description 15
- 238000000926 separation method Methods 0.000 claims abstract description 10
- 238000000605 extraction Methods 0.000 claims abstract description 8
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 7
- 238000011084 recovery Methods 0.000 claims abstract description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 10
- 229940090044 injection Drugs 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000005138 cryopreservation Methods 0.000 claims description 6
- 229960004452 methionine Drugs 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 238000009288 screen filtration Methods 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 229940093181 glucose injection Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- -1 Propylhomoserin compound Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 230000010148 water-pollination Effects 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 abstract description 5
- 208000036487 Arthropathies Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- RZHBMYQXKIDANM-UHFFFAOYSA-N dioctyl butanedioate;sodium Chemical compound [Na].CCCCCCCCOC(=O)CCC(=O)OCCCCCCCC RZHBMYQXKIDANM-UHFFFAOYSA-N 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of preparations comprising person joint's liquid excretion body, including following component：Person joint's liquid excretion body 20-30%, polyglycol solution 15-18%, human serum albumin 7-12%, methionine 6.5-7.5%, propylene carbonate 5.3-6.7%, Catergen .1-3.8%, tranexamic acid 1.35-2.28%, solvent 4.87-5.86%, phosphide acylsarcosine compound 5.66-7.32%, deionized water are surplus；The invention discloses a kind of application methods of preparation comprising person joint's liquid excretion body, include the following steps：The separation and Extraction of person joint's liquid excretion body, prepare preparation, degerming, recovery freeze and inject use；Formula design of the invention is more reasonable, obtains person joint's liquid excretion body by separation and Extraction, has good curative effect for treatment arthropathy, compares drug or operative treatment, and the use of the excretion body preparation is more safe, reduces the wound caused by patient body；And the excretion body preparation can be with long-term preservation after being made, and excretion body preparation is also very convenient when in use, and therapeutic effect is good, is conducive to promote and apply.
Description
Technical field
The present invention relates to field of biomedicine technology, specially a kind of preparation comprising person joint's liquid excretion body and its use
Method.
Background technique
Excretion body refers to that the small film bubble (30-150nm) for containing complicated RNA and protein refers in particular to diameter and exist now
The plate-like vesica of 40-100nm, nineteen eighty-three, excretion body are found in sheep granulophilocyte for the first time, Johnstone in 1987
It is named as " exosome "；Various kinds of cell can secrete excretion body under normal and pathological state, be mainly derived from cell
Interior lysosome particle invaginates the more vesica bodies to be formed, and is discharged into extracellular matrix after the external film of more vesicas and cell membrane fusion；
The cell type of all cultures can secrete excretion body, and excretion body is naturally present in body fluid, deposit in person joint's liquid excretion body
In excretion body, in the prior art for the treatment of person joint's disease frequently with drug or operative treatment, therapeutic effect is general, to disease
The wound that human body generates is larger, and at present to the treatment method of arthropathy, most of to play relaxation effect, can not
Fundamentally radical curing of disease, for this purpose, it is proposed that a kind of preparation and its application method comprising person joint's liquid excretion body.
Summary of the invention
The purpose of the present invention is to provide a kind of preparations and its application method comprising person joint's liquid excretion body, to solve to carry on the back
The problem of being proposed in scape technology.
To achieve the above object, the present invention provides the following technical solutions：A kind of preparation comprising person joint's liquid excretion body, packet
Include following component (by mass percentage)：Person joint's liquid excretion body 20-30%, polyglycol solution 15-18%, the white egg of people's blood
White 7-12%, methionine 6.5-7.5%, propylene carbonate 5.3-6.7%, Catergen .1-3.8%, tranexamic acid 1.35-
2.28%, solvent 4.87-5.86%, phosphide acylsarcosine compound 5.66-7.32%, deionized water are surplus.
Preferably, including following component (by mass percentage)：Person joint's liquid excretion body 20%, polyglycol solution
15%, human serum albumin 7%, methionine 6.5%, propylene carbonate 5.3%, Catergen .1%, tranexamic acid 1.35%, molten
Matchmaker 4.87%, phosphide acylsarcosine compound 5.66%, deionized water are surplus.
Preferably, including following component (by mass percentage)：Person joint's liquid excretion body 23%, polyglycol solution
16%, human serum albumin 8%, methionine 6.8%, propylene carbonate 5.7%, Catergen .6%, tranexamic acid 1.68%, molten
Matchmaker 5.14%, phosphide acylsarcosine compound 5.88%, deionized water are surplus.
Preferably, including following component (by mass percentage)：Person joint's liquid excretion body 27%, polyglycol solution
17%, human serum albumin 10%, methionine 7.2%, propylene carbonate 6.2%, vitamin C 3.5%, tranexamic acid 2.12%,
Solvent 5.48%, phosphide acylsarcosine compound 6.92%, deionized water are surplus.
Preferably, including following component (by mass percentage)：Person joint's liquid excretion body 30%, polyglycol solution
18%, human serum albumin 12%, methionine 7.5%, propylene carbonate 6.7%, vitamin C 3.8%, tranexamic acid 2.28%,
Solvent 5.86%, phosphide acylsarcosine compound 7.32%, deionized water are surplus.
Preferably, the solvent is any one of Multiple electrolytes injection, glucose injection or physiological saline；Institute
Phosphide acylsarcosine compound is stated to be made of the dioctylis sulfosuccinas natricus of phosphide acylsarcosine 45% and 55%.
A kind of preparation method of the preparation comprising person joint's liquid excretion body, includes the following steps：
Step 1：It takes person joint's liquid to be placed in sterile centrifugation tube, utilizes the excretion body in supercentrifugation separation joint fluid；
Centrifugation step is as follows：300g, 4 DEG C, 15 minutes；3000g, 4 DEG C, 15 minutes；20000g, 4 DEG C, 70 minutes；0.22 micron of sieve
Son filtering；120000g, 120 minutes, obtains person joint's liquid excretion body by 4 DEG C；
Step 2：Prepare preparation：Human serum albumin, methionine, vitamin and tranexamic acid is taken to be placed in high speed agitator,
It is stirred 15-25 minutes with the speed of 600-800 turns/min；Then propylene carbonate, phosphide acylsarcosine are added into blender
Compound, solvent and deionized water, improving mixing speed is that 1000-1200 turns/min, and temperature is maintained at 25-35 DEG C when stirring,
Centrifugal filtration 10-20 minutes after stirring, filtered fluid and person joint's liquid excretion body is taken to be mixed to get preparation；
Step 3：Degerming：Preparation obtained in step 2 is taken to be sent into filtration sterilization in degerming grade hydrophilic filters；It is hydrophilic
Property filter aperture be 0.1~1 μm；
Step 4：Recovery freezes：Preparation after taking filtration sterilization is added water bath with thermostatic control and recovers, and preparation is added and saves pipe
In, pre-cooling 20-30 minutes is then carried out, liquid nitrogen container cryopreservation is eventually adding；
Step 5：Injection uses：It takes out preparation and saves pipe, then carried out disinfection using syringe, syringe sucks preparation
The preparation in pipe is saved, is injected at patient articular.
Compared with prior art, the beneficial effects of the invention are as follows：Formula design of the invention is more reasonable, is mentioned by separation
Person joint's liquid excretion body is obtained, by adding human serum albumin, vitamin C, methionine, ammonia first ring to person joint's liquid excretion body
Substance needed for a variety of joint fluids such as acid, propylene carbonate has good curative effect for treatment arthropathy, controls compared to drug or operation
It treats, the use of the excretion body preparation is more safe, reduces the wound caused by patient body；And the excretion body preparation exists
Can be with long-term preservation after being made, excretion body preparation is also very convenient when in use, and highly-safe, therapeutic effect is good, conducive to pushing away
Wide application.
Specific embodiment
Below in conjunction with the embodiment of the present invention, technical scheme in the embodiment of the invention is clearly and completely described,
Obviously, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts, all
Belong to the scope of protection of the invention.
Embodiment one：
A kind of preparation comprising person joint's liquid excretion body, including following component (by mass percentage)：Outside person joint's liquid
Secrete body 20%, polyglycol solution 15%, human serum albumin 7%, methionine 6.5%, propylene carbonate 5.3%, vitamin
C2.1%, tranexamic acid 1.35%, solvent 4.87%, phosphide acylsarcosine compound 5.66%, deionized water are surplus.
Further, solvent is Multiple electrolytes injection；Phosphide acylsarcosine compound is by phosphide acylsarcosine 45%
It is formed with 55% dioctylis sulfosuccinas natricus.
A kind of preparation method of the preparation comprising person joint's liquid excretion body, includes the following steps：
Step 1：The separation and Extraction of person joint's liquid excretion body：Take person joint's liquid to be placed in sterile centrifugation tube, using hypervelocity from
Heart method separates the excretion body in joint fluid；Centrifugation step is as follows：300g, 4 DEG C, 15 minutes；3000g, 4 DEG C, 15 minutes；
20000g, 4 DEG C, 70 minutes；0.22 micron of screen filtration；120000g, 120 minutes, obtains person joint's liquid excretion body by 4 DEG C；
Step 2：Prepare preparation：Human serum albumin, methionine, vitamin and tranexamic acid is taken to be placed in high speed agitator,
It is stirred 15 minutes with the speed of 600 turns/min；Then into blender be added propylene carbonate, phosphide acylsarcosine compound,
Solvent and deionized water, raising mixing speed are 1000 turns/min, and temperature is maintained at 25 DEG C when stirring, is centrifuged after stirring
Filter 10 minutes takes filtered fluid and person joint's liquid excretion body to be mixed to get preparation；
Step 3：Degerming：Preparation obtained in step 2 is taken to be sent into filtration sterilization in degerming grade hydrophilic filters；It is hydrophilic
Property filter aperture be 0.1 μm；
Step 4：Recovery freezes：Preparation after taking filtration sterilization is added water bath with thermostatic control and recovers, and preparation is added and saves pipe
In, pre-cooling 20 minutes is then carried out, liquid nitrogen container cryopreservation is eventually adding；
Step 5：Injection uses：It takes out preparation and saves pipe, then carried out disinfection using syringe, syringe sucks preparation
The preparation in pipe is saved, is injected at patient articular.
Embodiment two：
A kind of preparation comprising person joint's liquid excretion body, including following component (by mass percentage)：Outside person joint's liquid
Secrete body 23%, polyglycol solution 16%, human serum albumin 8%, methionine 6.8%, propylene carbonate 5.7%, vitamin
C2.6%, tranexamic acid 1.68%, solvent 5.14%, phosphide acylsarcosine compound 5.88%, deionized water are surplus.
Further, solvent is glucose injection；Phosphide acylsarcosine compound is by 45% He of phosphide acylsarcosine
55% dioctylis sulfosuccinas natricus composition.
A kind of preparation method of the preparation comprising person joint's liquid excretion body, includes the following steps：
Step 1：The separation and Extraction of person joint's liquid excretion body：Take person joint's liquid to be placed in sterile centrifugation tube, using hypervelocity from
Heart method separates the excretion body in joint fluid；Centrifugation step is as follows：300g, 4 DEG C, 15 minutes；3000g, 4 DEG C, 15 minutes；
20000g, 4 DEG C, 70 minutes；0.22 micron of screen filtration；120000g, 120 minutes, obtains person joint's liquid excretion body by 4 DEG C；
Step 2：Prepare preparation：Human serum albumin, methionine, vitamin and tranexamic acid is taken to be placed in high speed agitator,
It is stirred 18 minutes with the speed of 650 turns/min；Then into blender be added propylene carbonate, phosphide acylsarcosine compound,
Solvent and deionized water, raising mixing speed are 1050 turns/min, and temperature is maintained at 28 DEG C when stirring, is centrifuged after stirring
Filter 13 minutes takes filtered fluid and person joint's liquid excretion body to be mixed to get preparation；
Step 3：Degerming：Preparation obtained in step 2 is taken to be sent into filtration sterilization in degerming grade hydrophilic filters；It is hydrophilic
Property filter aperture be 0.4 μm；
Step 4：Recovery freezes：Preparation after taking filtration sterilization is added water bath with thermostatic control and recovers, and preparation is added and saves pipe
In, pre-cooling 24 minutes is then carried out, liquid nitrogen container cryopreservation is eventually adding；
Step 5：Injection uses：It takes out preparation and saves pipe, then carried out disinfection using syringe, syringe sucks preparation
The preparation in pipe is saved, is injected at patient articular.
Embodiment three：
A kind of preparation comprising person joint's liquid excretion body, including following component (by mass percentage)：Outside person joint's liquid
Secrete body 27%, polyglycol solution 17%, human serum albumin 10%, methionine 7.2%, propylene carbonate 6.2%, vitamin
C3.5%, tranexamic acid 2.12%, solvent 5.48%, phosphide acylsarcosine compound 6.92%, deionized water are surplus.
Further, solvent is physiological saline；Phosphide acylsarcosine compound is by the sulphur of phosphide acylsarcosine 45% and 55%
Base sodium succinate dioctyl ester composition.
A kind of preparation method of the preparation comprising person joint's liquid excretion body, includes the following steps：
Step 1：The separation and Extraction of person joint's liquid excretion body：Take person joint's liquid to be placed in sterile centrifugation tube, using hypervelocity from
Heart method separates the excretion body in joint fluid；Centrifugation step is as follows：300g, 4 DEG C, 15 minutes；3000g, 4 DEG C, 15 minutes；
20000g, 4 DEG C, 70 minutes；0.22 micron of screen filtration；120000g, 120 minutes, obtains person joint's liquid excretion body by 4 DEG C；
Step 2：Prepare preparation：Human serum albumin, methionine, vitamin and tranexamic acid is taken to be placed in high speed agitator,
It is stirred 22 minutes with the speed of 750 turns/min；Then into blender be added propylene carbonate, phosphide acylsarcosine compound,
Solvent and deionized water, raising mixing speed are 1150 turns/min, and temperature is maintained at 33 DEG C when stirring, is centrifuged after stirring
Filter 17 minutes takes filtered fluid and person joint's liquid excretion body to be mixed to get preparation；
Step 3：Degerming：Preparation obtained in step 2 is taken to be sent into filtration sterilization in degerming grade hydrophilic filters；It is hydrophilic
Property filter aperture be 0.8 μm；
Step 4：Recovery freezes：Preparation after taking filtration sterilization is added water bath with thermostatic control and recovers, and preparation is added and saves pipe
In, pre-cooling 28 minutes is then carried out, liquid nitrogen container cryopreservation is eventually adding；
Step 5：Injection uses：It takes out preparation and saves pipe, then carried out disinfection using syringe, syringe sucks preparation
The preparation in pipe is saved, is injected at patient articular.
Example IV：
A kind of preparation comprising person joint's liquid excretion body, including following component (by mass percentage)：Outside person joint's liquid
Secrete body 30%, polyglycol solution 18%, human serum albumin 12%, methionine 7.5%, propylene carbonate 6.7%, vitamin
C3.8%, tranexamic acid 2.28%, solvent 5.86%, phosphide acylsarcosine compound 7.32%, deionized water are surplus.
Further, solvent is glucose injection；Phosphide acylsarcosine compound is by 45% He of phosphide acylsarcosine
55% dioctylis sulfosuccinas natricus composition.
A kind of preparation method of the preparation comprising person joint's liquid excretion body, includes the following steps：
Step 1：The separation and Extraction of person joint's liquid excretion body：Take person joint's liquid to be placed in sterile centrifugation tube, using hypervelocity from
Heart method separates the excretion body in joint fluid；Centrifugation step is as follows：300g, 4 DEG C, 15 minutes；3000g, 4 DEG C, 15 minutes；
20000g, 4 DEG C, 70 minutes；0.22 micron of screen filtration；120000g, 120 minutes, obtains person joint's liquid excretion body by 4 DEG C；
Step 2：Prepare preparation：Human serum albumin, methionine, vitamin and tranexamic acid is taken to be placed in high speed agitator,
It is stirred 25 minutes with the speed of 800 turns/min；Then into blender be added propylene carbonate, phosphide acylsarcosine compound,
Solvent and deionized water, raising mixing speed are 1200 turns/min, and temperature is maintained at 35 DEG C when stirring, is centrifuged after stirring
Filter 20 minutes takes filtered fluid and person joint's liquid excretion body to be mixed to get preparation；
Step 3：Degerming：Preparation obtained in step 2 is taken to be sent into filtration sterilization in degerming grade hydrophilic filters；It is hydrophilic
Property filter aperture be 1 μm；
Step 4：Recovery freezes：Preparation after taking filtration sterilization is added water bath with thermostatic control and recovers, and preparation is added and saves pipe
In, pre-cooling 30 minutes is then carried out, liquid nitrogen container cryopreservation is eventually adding；
Step 5：Injection uses：It takes out preparation and saves pipe, then carried out disinfection using syringe, syringe sucks preparation
The preparation in pipe is saved, is injected at patient articular.
The preparation of excretion body can be made in above four groups of embodiments, and formula design of the invention is more reasonable, passes through
Separation and Extraction obtains person joint's liquid excretion body, by person joint's liquid excretion body add human serum albumin, vitamin C, methionine,
Substance needed for a variety of joint fluids such as tranexamic acid, propylene carbonate has good curative effect for treatment arthropathy, compared to drug or
The use of operative treatment, the excretion body preparation is more safe, reduces the wound caused by patient body；And the excretion body
Preparation can be with long-term preservation after being made, and excretion body preparation is also very convenient when in use, and highly-safe, therapeutic effect is good,
Conducive to popularization and application.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (7)
1. a kind of preparation comprising person joint's liquid excretion body, which is characterized in that including following component (by mass percentage)：People
Joint fluid excretion body 20-30%, polyglycol solution 15-18%, human serum albumin 7-12%, methionine 6.5-7.5%, propylene
Carbonic ester 5.3-6.7%, Catergen .1-3.8%, tranexamic acid 1.35-2.28%, solvent 4.87-5.86%, phosphatidyl flesh
Propylhomoserin compound 5.66-7.32%, deionized water are surplus.
2. a kind of preparation comprising person joint's liquid excretion body according to claim 1, which is characterized in that including following component
(by mass percentage)：Person joint's liquid excretion body 20%, polyglycol solution 15%, human serum albumin 7%, methionine
6.5%, propylene carbonate 5.3%, Catergen .1%, tranexamic acid 1.35%, solvent 4.87%, phosphide acylsarcosine are compound
Object 5.66%, deionized water are surplus.
3. a kind of preparation comprising person joint's liquid excretion body according to claim 1, which is characterized in that including following component
(by mass percentage)：Person joint's liquid excretion body 23%, polyglycol solution 16%, human serum albumin 8%, methionine
6.8%, propylene carbonate 5.7%, Catergen .6%, tranexamic acid 1.68%, solvent 5.14%, phosphide acylsarcosine are compound
Object 5.88%, deionized water are surplus.
4. a kind of preparation comprising person joint's liquid excretion body according to claim 1, which is characterized in that including following component
(by mass percentage)：Person joint's liquid excretion body 27%, polyglycol solution 17%, human serum albumin 10%, methionine
7.2%, propylene carbonate 6.2%, vitamin C 3.5%, tranexamic acid 2.12%, solvent 5.48%, phosphide acylsarcosine are compound
Object 6.92%, deionized water are surplus.
5. a kind of preparation comprising person joint's liquid excretion body according to claim 1, which is characterized in that including following component
(by mass percentage)：Person joint's liquid excretion body 30%, polyglycol solution 18%, human serum albumin 12%, methionine
7.5%, propylene carbonate 6.7%, vitamin C 3.8%, tranexamic acid 2.28%, solvent 5.86%, phosphide acylsarcosine are compound
Object 7.32%, deionized water are surplus.
6. a kind of preparation comprising person joint's liquid excretion body according to claim 1, it is characterised in that：The solvent is multiple
Any one of square electrolyte injection, glucose injection or physiological saline；The phosphide acylsarcosine compound is by phosphide
The dioctylis sulfosuccinas natricus of acylsarcosine 45% and 55% composition.
7. a kind of preparation method of the preparation comprising person joint's liquid excretion body as described in claim 1-6, which is characterized in that packet
Include following steps：
Step 1：The separation and Extraction of person joint's liquid excretion body：It takes person joint's liquid to be placed in sterile centrifugation tube, utilizes supercentrifugation
Separate the excretion body in joint fluid；Centrifugation step is as follows：300g, 4 DEG C, 15 minutes；3000g, 4 DEG C, 15 minutes；20000g, 4
DEG C, 70 minutes；0.22 micron of screen filtration；120000g, 120 minutes, obtains person joint's liquid excretion body by 4 DEG C；
Step 2：Prepare preparation：Human serum albumin, methionine, vitamin and tranexamic acid is taken to be placed in high speed agitator, with
The speed of 600-800 turns/min stirs 15-25 minutes；Then it is multiple that propylene carbonate, phosphide acylsarcosine are added into blender
Object, solvent and deionized water are closed, improving mixing speed is that 1000-1200 turns/min, and temperature is maintained at 25-35 DEG C when stirring, is stirred
Centrifugal filtration 10-20 minutes after mixing, filtered fluid and person joint's liquid excretion body is taken to be mixed to get preparation；
Step 3：Degerming：Preparation obtained in step 2 is taken to be sent into filtration sterilization in degerming grade hydrophilic filters；Hydrophily mistake
The aperture of filter is 0.1~1 μm；
Step 4：Recovery freezes：Preparation after taking filtration sterilization is added water bath with thermostatic control and recovers, and preparation is added and saves in pipe,
Then pre-cooling 20-30 minutes is carried out, liquid nitrogen container cryopreservation is eventually adding；
Step 5：Injection uses：It takes out preparation and saves pipe, then carried out disinfection using syringe, syringe sucks preparation and saves
Preparation in pipe, is injected at patient articular.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810803915.4A CN108815187A (en) | 2018-07-20 | 2018-07-20 | A kind of preparation and its application method comprising person joint's liquid excretion body |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810803915.4A CN108815187A (en) | 2018-07-20 | 2018-07-20 | A kind of preparation and its application method comprising person joint's liquid excretion body |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108815187A true CN108815187A (en) | 2018-11-16 |
Family
ID=64139717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810803915.4A Pending CN108815187A (en) | 2018-07-20 | 2018-07-20 | A kind of preparation and its application method comprising person joint's liquid excretion body |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108815187A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110840915A (en) * | 2019-11-25 | 2020-02-28 | 深圳市第二人民医院 | Preparation method and application of targeted mesenchymal stem cell exosome |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015803A1 (en) * | 2001-08-14 | 2003-02-27 | Trans Tissue Technologies Gmbh | Cell compositions for use in the treatment of osteo-arthrosis, and method for producing the same |
| WO2004050103A1 (en) * | 2002-12-03 | 2004-06-17 | Meader Charles P | Replacement joint fluid |
| CN105483081A (en) * | 2015-11-13 | 2016-04-13 | 中国人民解放军第二军医大学 | MiRNA145-5p-modified umbilical cord mesenchymal stem cell exosome and preparation and application of miRNA145-5p-modified umbilical cord mesenchymal stem cell exosome |
| CN106399250A (en) * | 2015-07-31 | 2017-02-15 | 广州市锐博生物科技有限公司 | Method and kit for separating exosome |
| CN106539821A (en) * | 2016-11-30 | 2017-03-29 | 广州赛莱拉干细胞科技股份有限公司 | A kind of stem cell excretion body preparation and its preparation method and application |
| CN107223153A (en) * | 2015-02-04 | 2017-09-29 | 胞外体干细胞株式会社 | Efflux body comprising the stem cell for coming from positive differentiating cartilage-forming cell be used for Chondrocyte Differentiation induce or regenerative agent of cartilaginous tissue composition |
| CN107823632A (en) * | 2017-11-10 | 2018-03-23 | 南京九圣生物科技股份有限公司 | A kind of mesenchymal stem cells MSCs parenteral solution and preparation method |
| CN107898810A (en) * | 2017-12-20 | 2018-04-13 | 北京臻惠康生物科技有限公司 | A kind of mescenchymal stem cell repairs parenteral solution and preparation method thereof |
| CN107980004A (en) * | 2015-06-10 | 2018-05-01 | 得克萨斯州大学系统董事会 | Purposes for the excretion body for the treatment of disease |
-
2018
- 2018-07-20 CN CN201810803915.4A patent/CN108815187A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015803A1 (en) * | 2001-08-14 | 2003-02-27 | Trans Tissue Technologies Gmbh | Cell compositions for use in the treatment of osteo-arthrosis, and method for producing the same |
| WO2004050103A1 (en) * | 2002-12-03 | 2004-06-17 | Meader Charles P | Replacement joint fluid |
| CN107223153A (en) * | 2015-02-04 | 2017-09-29 | 胞外体干细胞株式会社 | Efflux body comprising the stem cell for coming from positive differentiating cartilage-forming cell be used for Chondrocyte Differentiation induce or regenerative agent of cartilaginous tissue composition |
| CN107980004A (en) * | 2015-06-10 | 2018-05-01 | 得克萨斯州大学系统董事会 | Purposes for the excretion body for the treatment of disease |
| CN106399250A (en) * | 2015-07-31 | 2017-02-15 | 广州市锐博生物科技有限公司 | Method and kit for separating exosome |
| CN105483081A (en) * | 2015-11-13 | 2016-04-13 | 中国人民解放军第二军医大学 | MiRNA145-5p-modified umbilical cord mesenchymal stem cell exosome and preparation and application of miRNA145-5p-modified umbilical cord mesenchymal stem cell exosome |
| CN106539821A (en) * | 2016-11-30 | 2017-03-29 | 广州赛莱拉干细胞科技股份有限公司 | A kind of stem cell excretion body preparation and its preparation method and application |
| CN107823632A (en) * | 2017-11-10 | 2018-03-23 | 南京九圣生物科技股份有限公司 | A kind of mesenchymal stem cells MSCs parenteral solution and preparation method |
| CN107898810A (en) * | 2017-12-20 | 2018-04-13 | 北京臻惠康生物科技有限公司 | A kind of mescenchymal stem cell repairs parenteral solution and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| YU ZHU等: ""Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis"" * |
| 高 坤等: "\"类风湿关节炎和骨关节炎发病及治疗中的外泌体\"" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110840915A (en) * | 2019-11-25 | 2020-02-28 | 深圳市第二人民医院 | Preparation method and application of targeted mesenchymal stem cell exosome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chahla et al. | Bone marrow aspirate concentrate harvesting and processing technique | |
| US6841170B2 (en) | Process for preparing an autologous platelet gel and membrane thereof | |
| ES2649387T3 (en) | Method for preparing tissues, particularly adipose tissue | |
| KR101922538B1 (en) | Process, tube and device for the preparation of wound healant composition | |
| EP2884992B1 (en) | A method of preparing a growth factor concentrate derived from human platelets | |
| CN106038478B (en) | A kind of porous microsphere of glucose-sensitive/polymer plural gel and its preparation method and application | |
| CN108114273A (en) | A kind of perfluocarbon albumin nano granular and preparation method and application | |
| CN108715834A (en) | A kind of platelet lysates liquid and preparation method thereof rich in CD41+, CD81+ micro-capsule | |
| US9205110B2 (en) | Enhanced autologous growth factor production and delivery system | |
| CN107951904B (en) | Adipose-derived mesenchymal stem cell medicine and preparation method and application thereof | |
| CN108815187A (en) | A kind of preparation and its application method comprising person joint's liquid excretion body | |
| Davis et al. | Cosmetic fat transplantation: a review | |
| CN108542916A (en) | It is a kind of to be used to treat arthral fluid mescenchymal stem cell preparation of Osteoarthritis and preparation method thereof | |
| CN109125806A (en) | A kind of subcutaneous injection stem cell microsphere gel compound and its application | |
| CN110433320A (en) | A kind of preparation method of medical dressing | |
| WO2014027359A1 (en) | A growth factor concentrate for treating tendinopathies | |
| US20050106128A1 (en) | Novel methods of treatment and deliver modes | |
| AU2002356465A1 (en) | Methods of treatment in situ in the lungs of mammals | |
| TWM589033U (en) | Blood separation assembly and blood separation tube | |
| CN114732833B (en) | Stem cell biological agent containing PRP and application thereof | |
| CN113831742B (en) | Preparation method and application of PRP-containing biological ink | |
| CN103361298A (en) | Separation and extraction fluid suitable for pig pancreas islet and preparation and application thereof | |
| US20240269173A1 (en) | Biological Fluid Concentration Devices and Methods of Use | |
| WO2014027361A1 (en) | A growth factor concentrate for treating periorbital hyperpigmentation | |
| CN109172604A (en) | A kind of MSC hydrogel composites and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181116 |
|
| RJ01 | Rejection of invention patent application after publication |